@limnopharma.com
Developing medicines for diseases affecting the retina.
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Limno Pharma is a groundbreaking brand that focuses on developing new therapies for retinal diseases. With over 200 million people worldwide affected by these conditions, Limno Pharma aims to provide solutions where there are currently none or where existing treatments are costly and invasive. Specifically, their initial focus is on two retinal diseases: Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP).
Limno Pharma was founded in March 2019 based on scientific research conducted by doctors Juan Carlos Morales Sánchez and Francisco Díaz Corrales. Their research led to the discovery and validation of the compounds LIM21 and LIM109, which have shown effective in animal models of the diseases. Limno Pharma holds exclusive global rights to these compounds through two patents.
The goal of Limno Pharma is to complete preclinical and clinical phases I and II of the compounds' development, obtaining approval to begin clinical trials. With an experienced team, including CEO Elena Puerta Fernández, Limno Pharma is dedicated to bringing these potential medications to market and revolutionizing the treatment of retinal diseases
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online